The purpose of this study was to evaluate the role of sequence variants in the CYP2C8, ABCB1 and CYP3A4 genes and the CYP3A4 phenotype for the pharmacokinetics and toxicity of paclitaxel in ovarian cancer patients. Thirty-eight patients were treated with paclitaxel and carboplatin. The genotypes of CYP2C8*1B,*1C, *2, *3, *4, *5, *6, *7, *8 and P404A, ABCB1 G2677T/A and C3435T, as well as CYP3A4*1B, were determined by pyrosequencing. Phenotyping of CYP3A4 was performed in vivo with quinine as a probe. The patients were monitored for toxicity and twenty-three patients underwent a more extensive neurotoxicity evaluation. Patients heterozygous for G/A in position 2677 in ABCB1 had a significantly higher clearance of paclitaxel than most other ABCB1 variants. A lower clearance of paclitaxel was found for patients heterozygous for CYP2C8*3 when stratified according to the ABCB1 G2677T/A genotype. In addition, the CYP3A4 enzyme activity in vivo affected which metabolic pathway was dominant in each patient, but not the total clearance of paclitaxel. The exposure to paclitaxel correlated to the degree of neurotoxicity.
Introduction
Paclitaxel in combination with carboplatin is the standard chemotherapy for ovarian cancer.
Carboplatin doses are adjusted according to the renal function, whereas paclitaxel is used in standardized doses according to body surface area. The pharmacokinetics and the response to paclitaxel treatment vary greatly among individuals and one factor of importance for these differences might be the genetic variability. Our belief is that it would be important to be able to predict the highest yet safe starting dose for each individual to avoid undertreatment.
Understanding the mechanisms behind the interindividual differences in the pharmacokinetics of paclitaxel should be the foundation for establishing individual dosages.
It has been suggested that the pharmacokinetics of paclitaxel are affected by several proteins, such as metabolic enzymes and drug transporters [1] . Systemic elimination of paclitaxel occurs by hepatic metabolism involving the cytochrome P450 (CYP) enzymes, CYP3A4 and CYP2C8 [2] . Paclitaxel is converted to p-3'-hydroxypaclitaxel by CYP3A4 [3] and CYP2C8
catalyzes the formation of 6 -hydroxypaclitaxel [4] . These metabolites can be further oxidized to 6 -, p-3'-dihydroxypaclitaxel [4, 5] . All three metabolites are less potent than the parent compound in inhibiting cell growth in vitro [6, 7] . Several single nucleotide polymorphisms (SNPs) have been reported in the CYP2C8 gene and some alleles (*2, *3, *7, *8 and P404A) have been associated with decreased 6α-hydroxypaclitaxel production in vitro [8] [9] [10] [11] . The CYP2C8*5 allele, a premature stop-codon, is also expected to encode an inactive protein [12] . However, the effects of the polymorphisms on paclitaxel pharmacokinetics in vivo are still unclear. The large interindividual variation in CYP3A4 activity is more difficult to explain on a genetic basis [13] , although the CYP3A4*1B seems to affect enzyme activity [14] . Therefore several groups have developed and validated probes for determination of the CYP3A4 activity in vivo [14] [15] [16] . 2010-05-27
Paclitaxel is also a substrate for P-glycoprotein, a 170 kDa plasma membrane protein encoded by the ABCB1 gene that functions as an ATP-driven drug export pump. P-glycoprotein is believed to be an important factor in the resistance to [17, 18] and biliary elimination of many drugs, including paclitaxel [19, 20] . Different polymorphisms in the ABCB1 gene have been identified and of these SNPs, the linked G2677T/A (Ala893Ser/Thr) and C3435T (Ile1145Ile, wobble) have been associated with altered P-glycoprotein expression and phenotype [21] [22] [23] . Recently we showed that SNPs in the ABCB1 gene affect the response to paclitaxel treatment in ovarian cancer [24] , although another study did not find the same correlation [25] .
We initiated this pilot study to investigate the feasibility of genotyping ovarian cancer for CYP3A4, CYP2C8 and ABCB1 sequence variants and CYP3A4phenotyping in vivo and its correlation to the pharmacokinetics and toxicity of paclitaxel as a basis for individualized chemotherapy.
Material and Methods

Patient selection and characteristics:
A total of 38 Caucasian women to be treated with paclitaxel at 175 mg/m 2 in combination with carboplatin (AUC 5 or 6 according to Calvert's formula) were included in the study. Paclitaxel was administered intravenously during a 3-h infusion at a dose of 175 mg/m 2 (n = 35) or 135 mg/m 2 (n = 3, dose reduction due to poor general condition) and at least six cycles of paclitaxel-containing chemotherapy were given (except for two patients, one received only one cycle due to septicemia and one patient was withdrawn from further paclitaxel treatment after four cycles due to severe neurotoxicity).
The pharmacokinetic sampling was done during one cycle for each patient. Twenty-four patients were chemotherapy naive and nine were treated after relapse. In 30 patients the diagnosis and histology were consistent with epithelial ovarian cancer and in 5 patients with peritoneal cancer. Remaining patients suffered from carcinoma in corpus uteri (n = 1), in cervix uteri (n = 1) and cancer of uncertain origin (ovarian or peritoneal, n = 1). No patient was on medication with digoxin, quinidine, ketoconazole or had previously shown any hypersensitivity against quinine or quinidine. The patients and tumour characteristics for those patients assessed for pharmacokinetics are presented in table 1.
This study was approved by the regional ethics committees and written informed consent was obtained from each patient.
Sampling and pharmacokinetic studies: Prior to chemotherapy (24-48 h) a 250 mg quinine tablet was given to the patient and a blood sample was drawn 16 h later in a heparinized tube to assess the in vivo CYP3A4 activity, as previously described [26, 27] . For pharmacokinetic analysis, blood samples were collected in EDTA tubes at the following time points:
immediately before infusion of paclitaxel, 30 min and 1 h after start of infusion, immediately before stop of infusion, 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h and 24 h after stop of infusion. Five patients were excluded from pharmacokinetic assessment due to incomplete sampling. After centrifugation, plasma samples were stored at -80°C until analysis. The rest of the blood samples were stored for DNA-extraction. We determined the concentrations of paclitaxel, 6α-hydroxypaclitaxel and p-3'-hydroxypaclitaxel using solid phase extraction, reverse-phase high-performance liquid chromatography and an ion trap mass spectrometer with a sonic spray ionization interphase, as described by Green et al. [28] . The areas under the plasma concentration-time curve (AUC 0-24h ) were calculated using the trapezoid method (AUC 24h-< 5%). Nscore [29] . The patients were also asked to rate their inconveniences due to neurological adverse effects on a scale from 0 = no notice of neurological adverse effects to 5 = unbearable. Both the patients' rating and Nscore at first response evaluation and at the final cycle were used for evaluation of the patient's individual neurotoxicity.
DNA isolation, PCR and pyrosequencing:
Genomic DNA was isolated using QIAamp ® DNA mini-kits (VWR International, Stockholm, Sweden) according to the manufacturer's protocol.
The quantity of DNA extracted was determined using absorbance spectroscopy (260 and 280 nm) and the DNA was diluted to 10 ng/µl for working solutions and stored at -20 C.
The PCR primers (table 2) for amplification of the genes were designed using the website Primer3 (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) and checked for specificity using the NCBI BLAST server (http://www.ncbi.nlm.nih.gov/blast/). One primer for each PCR product was biotinylated in its 5'-end for purification of single-stranded DNA.
The sequencing primers were designed using the Pyrosequencing SNP primer Design Version 2010-05-27 The sequences of all PCR products were verified using both forward and reverse primers on a MegaBACE 1000 (Amersham Biosciences, Uppsala, Sweden) and the sequences were consistent with the GenBank sequences AC005068 for ABCB1, AF136830-43 for CYP2C8
and AF280107 for CYP3A4.
The SNPs were analyzed by a Pyrosequencing PSQ96MA (Biotage, Uppsala, Sweden)
according to the manufacturer's protocol and as previously described. [24] In short, for each genotype, single-stranded DNA was isolated from the PCR reactions using the 
Results
The pharmacokinetics of paclitaxel showed high interindividual variability as shown in table 3. Genotypes both in the patients and in a Swedish reference population were found to be in Hardy-Weinberg equilibrium (table 4). Some polymorphisms described in the literature could not be detected in our population. 
Paclitaxel pharmacokinetics, genotypes and CYP3A4 in vivo activity
Discussion
In this pilot study, we found that the clearance of paclitaxel was influenced by the SNPs G2677T/A in ABCB1 and CYP2C8*3. The neurotoxicity correlated with the exposure to paclitaxel. In addition, the CYP3A4 enzyme activity in vivo affected the pathway of paclitaxel metabolism but not the total clearance. The genotypes found had similar allele frequencies in the patient and the reference populations and were in accordance with previous studies [8, 30, 31] .
In this study patients heterozygous for CYP2C8*3 had a lower paclitaxel clearance compared to wild-type patients, which is in accordance with the lower V max [11] and enzyme activity [9] found for recombinant CYP2C8*3 as compared to the wild type. Liver microsomes heterozygous for CYP2C8*3 (n=19) also had a lower paclitaxel 6-hydroxylase activity as compared to the wild type [8] , although the activity did overlap and the results could not be reproduced in a smaller study (n=4) [32] .
The CYP3A4 activity affected the metabolite pattern, but not the clearance of paclitaxel. A low activity correlated to a high AUC 0-24h of 6α-hydroxypaclitaxel indicating that in patients with low CYP3A4 activity a higher proportion of paclitaxel is converted by CYP2C8.
We found that the G2677T/A SNP affect the clearance of paclitaxel. Patients carrying the G/A had a significantly higher clearance whereas patients homozygous for T/T had the lowest clearance of paclitaxel. We have previously shown that patients with two non wild type alleles in position 2677 (T/T or T/A) have a better response to paclitaxel treatment [24] , although others have presented different results [25] . This effect can also be explained by an altered transport activity at the tumour site in combination with a change in clearance. The functional consequences of these SNPs on the transport of P-glycoprotein has not been studied extensively in vitro [23, [33] [34] [35] [36] . Schaefer et al. showed that the T and A genetic variants in position 2677 had significantly different transport capacity, the maximum transport velocities of vincristine were increased by 1.5 and three-fold for the Ser893 (2677T) and the Thr893 (2677A) variants, respectively [36] . This is in accordance with our findings of a higher paclitaxel clearance for patients with the 2677G/A genetic variant, although only 3 patients with this variant were found. In another study the wild type showed a slightly higher efflux of paclitaxel than the Ser893 variant [33] , in agreement with our results but in contrast to genotype and the pharmacokinetics of paclitaxel either, although the study is small (n = 26) and the difference in AUC of paclitaxel approaches significance (P = 0.18) for G2677T/A and C3435T [39] . In a study of dose-intense paclitaxel, doxorubicin and cyclophosphamide treatment of breast cancer no correlations were found between the genotype of several genes including CYP3A4, ABCB1 and CYP2C8 and paclitaxel clearance [40] . However, the higher dose (575-775 mg/m 2 ) of paclitaxel and longer infusion time (24h) might explain the discrepancy compared to our result. A study in a Caucasian population investigated the clearance of unbound paclitaxel in cancer patients receiving paclitaxel as an i.v. infusion for 2010-05-27
1, 3 or 24 h at a dose of 80-225 mg/m 2 .
[41] The patients were genotyped for CYP2C8*2, CYP2C8*3, CYP2C8*4, CYP3A4*3, CYP3A5*3C and ABCB1 C3435T. Although they found a high interindividual variation in clearance of unbound paclitaxel (10-fold), no statistical significant association was observed between any variant genotype and the pharmacokinetics of paclitaxel [41] . This is in contradiction to our findings concerning a reduced elimination of paclitaxel in patients heterozygous for CYP2C8*3. Most in vitro studies as well as findings for repaglinide [42] and ibuprofen [43] for, and we had to stratify the data accordingly to evaluate the effect of CYP2C8*3.
The exposure of paclitaxel was significantly correlated to the neurotoxicity at the final chemotherapy cycle. The patient's own grading of her neurological inconvenience at cycle 3 or 4 was associated with the exposure to paclitaxel, but not at the final cycle of chemotherapy, which might be due to dose reductions at later cycles. We also found a correlation between CYP2C8*3 and neuropathy, which is in accordance with the lower clearance of paclitaxel associated with this genotype. Previous studies have also shown that the paclitaxel exposure is associated with the degree of neurotoxicity [38, 44] as well as overall survival [45] and the response at end of chemotherapy [46] . Neuropathy has also been shown to correlate to the genotype of ABCB1 [39] . Patients with wild type for C3435T did not develop neuropathy as fast as other patients. 2010-05-27
In conclusion these results show that genotyping might be a feasible approach for individualised chemotherapy of paclitaxel. It has been shown that a higher plasma concentration and especially the duration of paclitaxel concentrations above a threshold correlates with the response to chemotherapy [45] [46] [47] as well as to the toxicity [44, 47, 48] . In this study, we found that the clearance of paclitaxel is influenced by the SNPs G2677T/A in ABCB1 and CYP2C8*3, and that the neurotoxicity correlates with the exposure to paclitaxel.
However, results from larger studies are necessary before paclitaxel dosages can be individualized according to the patient's pharmacogenetic profile. Note: * No significant difference could be found between male and females in the reference population. The 95% confidence intervals for the allele frequencies are given as +/-values. † CYP2C8*1C and *4 were present in a linkage disequilibrium and CYP2C8*1B was present mutually exclusive of *1C, *3 and *4. 2010-05-27
Figure Legends 
Fig. 2.
Correlation between the AUC 0-24h of paclitaxel and the severity of the neurotoxicity (Nscore) at A) first response evaluation (cycle 3 or 4) and at B) the final cycle of chemotherapy. Fig. 3 . Correlation of paclitaxel exposure (AUC 0-24h ) to the patients' own rating of their inconveniences due to neurological adverse effects at A) the first response evaluation (cycle 3 or 4) and at B) the final cycle of chemotherapy.
